Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | PDE7A | Q13946 | 10/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.56 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451645 | 0.87 | L3MBTL1 (0.73) | L3MBTL1PDE7ALMNAALDH1A1HPGD | |
| SCHEMBL7891889 | 0.76 | L3MBTL1 (0.62) | L3MBTL1PDE7ALMNAALDH1A1PDE4B | |
| SCHEMBL18997470 | 0.75 | L3MBTL1 (0.62) | L3MBTL1PDE7ALMNAALDH1A1HPGD | |
| SCHEMBL10175968 | 0.75 | RECQL (0.75) | L3MBTL1LMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5477516 | 0.72 | ALDH1A1 (0.50) | L3MBTL1PDE7ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12713425 | 0.69 | LMNA (0.78) | L3MBTL1LMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11046960 | 0.69 | ALDH1A1 (0.54) | L3MBTL1PDE7ALMNAALDH1A1PDE4B | |
| SCHEMBL20152123 | 0.69 | ALDH1A1 (0.64) | L3MBTL1PDE7ALMNAALDH1A1PDE4B | |
| SCHEMBL5437926 | 0.68 | SMN1; SMN2 (0.67) | L3MBTL1LMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12713388 | 0.68 | LMNA (0.63) | L3MBTL1PDE7ALMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264760-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20100022547-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | BRANDEIS UNIVERSITY (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264760-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | IMPDH1, IMPDH2, ITPA | L3MBTL1 2751/4885PDE7A 86/4885LMNA 3931/4885 |
| US-20100022547-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections | IMPDH1, IMPDH2, ITPA | L3MBTL1 2751/4885PDE7A 86/4885LMNA 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.